Showing results (1-10 of 111) with videos related to
Sort By:
Pageof 12
Expert Opinion on Therapeutic Targets|October 9, 2020
Systemic lupus erythematosus (SLE): emerging therapeutic targetsLauren M Mathias, William StohlExpert Opinion on Therapeutic Targets|May 27, 2004
Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disordersWilliam StohlArthritis Research & Therapy|May 2, 2003
SLE--systemic lupus erythematosus: a BLySful, yet BAFFling, disorderWilliam StohlCurrent Rheumatology Reports|July 20, 2002
B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseasesWilliam StohlCurrent Rheumatology Reports|May 2, 2012
Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development?William StohlNature Reviews. Rheumatology|September 11, 2013
Future prospects in biologic therapy for systemic lupus erythematosusWilliam StohlExpert Review of Clinical Immunology|February 7, 2017
Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE)William StohlArthritis Research & Therapy|May 6, 2010
Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes)William StohlExpert Opinion on Therapeutic Targets|February 14, 2014
Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosusWilliam StohlCurrent Opinion in Rheumatology|August 23, 2002
Systemic lupus erythematosus: a blissless disease of too much BLyS (B lymphocyte stimulator) proteinWilliam StohlPageof 12